AOD-9604 vs Retatrutide
A side-by-side research comparison of AOD-9604 and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Retatrutide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 1815.08 Da | 5,200 Da (approximate) |
| Half-life | ~2-3 hours | 6 days |
| Bioavailability | ~90% subcutaneous | High (SubQ) |
| Typical dose | 300 mcg | 1-2 mg → titrate up to 12 mg |
| Frequency | Daily (morning, fasted) | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.